Lantern Pharma (LTRN) Reports Q1 Loss of $0.51
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LTRN Hot Sheet
Join SI Premium – FREE
Lantern Pharma (NASDAQ: LTRN) reported Q1 EPS of ($0.51).
For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CoreCivic (CXW) Misses Q3 EPS by 1530c; raises guidance
- Primerica (PRI) Tops Q3 EPS by 37c, Beats on Revenue
- Liberty Latin America (LILA) Reports Q3 results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
